Cyprumed reports MSD Phase 1 trial of its oral peptide-delivery technology

Cyprumed said on September 29 that MSD has initiated a Phase 1 trial of a proprietary drug candidate formulated with its oral tablet technology. The development brings the Austrian company’s peptide-delivery platform into human testing, a necessary step toward determining whether its formulation approach can support a practical medicine.

The announcement contains no human safety or efficacy results. It also leaves the candidate unnamed, limiting what can be concluded about the disease being targeted or the potential relevance to chronic disease care.

What has been disclosed

According to Cyprumed, this is the first program using its technology to enter clinical development. The study follows a licensing agreement announced in April 2025 and triggers a milestone payment from MSD, known as Merck & Co. in the United States and Canada.

The release does not identify a trial registration number, enrollment target, participant population, comparator or prespecified endpoints. It reports that the trial has begun without specifying the first participant’s dosing date. September 29 is therefore the announcement date, rather than a verified date for the start of treatment.

Why peptide absorption matters

An oral peptide formulation must negotiate several biological obstacles. Digestive enzymes can degrade the molecule, while limited passage across the gastrointestinal lining can restrict how much reaches the circulation. A 2025 review in the International Journal of Pharmaceutics describes stability, permeability and low bioavailability as continuing challenges for the field.

These constraints make formulation part of the scientific question. A tablet’s convenience has clinical value only if it delivers sufficiently reliable exposure while maintaining acceptable safety. Success with one peptide cannot automatically establish that another molecule will behave similarly.

Earlier animal work offers context

A separate study involving Cyprumed researchers, published online in the Journal of Controlled Release on August 22, 2025, examined intestinal targeting of semaglutide in pigs. Its objectives included evaluating imaging methods, identifying where coated capsules released their contents and measuring drug absorption.

Researchers placed capsules containing a semaglutide tablet and an imaging contrast material directly into the duodenum using an endoscope while the animals were anesthetized. They then monitored release with imaging and compared pharmacokinetic measurements between formulations.

Release farther along the small intestine was associated with greater semaglutide absorption. That finding supports investigating how release location affects delivery, but the experiment bypassed normal swallowing and stomach transit. It did not establish effectiveness in people or demonstrate that patients would experience better disease control.

Several authors disclosed affiliations with Cyprumed. The paper provides relevant preclinical context, but the September announcement does not establish that the new MSD trial uses the same molecule or formulation. Semaglutide should therefore not be identified as the clinical candidate.

What human testing must resolve

MSD’s general description of clinical development explains that Phase 1 studies address initial safety, dose-related questions and side effects. Larger subsequent studies investigate therapeutic effectiveness and longer-term performance. Those general purposes should not be mistaken for the undisclosed protocol of this particular trial.

For an oral delivery platform, useful evidence would include reproducible drug exposure, variability between participants and tolerability. Comparisons under different meal conditions could help establish whether a formulation is practical for everyday use. These are questions for future disclosed data, not findings from the announcement.

The potential connection to healthspan is indirect: easier administration could matter for sustained management of chronic illness, but only if clinical studies establish a useful treatment. This milestone supplies no evidence of improved adherence, fewer complications or longer healthy life. The next consequential development will be a disclosed trial record or human results that allow the platform’s performance to be assessed.